FAT10 is an oncogene that is localized at 6q21.3, a region frequently amplified in hepatocellular carcinoma (HCC). Recently, growing attention has been paid to its effect in the initiation of various cancers. However, there has been little research into the influence of FAT10 on the progression and prognosis of HCC, especially in hepatitis B virus (HBV)-related HCC. Here, we aimed at investigating clincopathological significance of FAT10 in HBV-related HCC and its underlying mechanisms. Based on the analysis of FAT10 expression in a reliable and large number of cases with 5-year follow-up, we showed that FAT10 was significantly increased in 260 samples from HBV-related HCC patients, compared with 30 normal tissue, 50 cirrhosis and matched adjacent nontumor tissues. FAT10 expression is correlated with recurrence and poor prognosis in HBV-related HCC. In addition, ectopic expression of FAT10 enhanced cell proliferation, inhibited apoptosis and induced cell cycle progression, whereas silencing FAT10 expression suppressed cell proliferation and induced apoptosis. FAT10 also induced the epithelial-mesenchymal transition (EMT) and promoted invasion of HCC cells. Furthermore, we found Akt/GSK3b pathway contributed to the effects of FAT10 in HCC cells. Blocking the Akt pathway significantly inhibited the actions of FAT10. Taken together, the ubiquitin-like protein FAT10 has a central role in regulating diverse aspects of the pathogenesis of HCC, indicating that it might be a potential therapeutic target.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer-related mortality worldwide. 1, 2 In China, HCC has become the second highest cause of cancer death, and chronic hepatitis B virus (HBV) infection is a major risk factor for HCC. 3 Partial liver resection or orthotopic liver transplantation is regarded as the standard curative treatments for HCC. However, the long-term prognosis following surgery remains unsatisfactory because of the high rate of intrahepatic recurrence and lack of effective adjuvant therapy to prevent recurrence. 4 Thus, it is important to investigate the molecular mechanisms of HCC and identify markers of its prognosis and progression.
Human FAT10 was originally discovered through identification of expressed genes from the HLA-F genomic locus. 5 It is constitutively expressed in mature dendritic cells, B cells and the immune organs such as thymus and spleen, 5, 6 but it is also inducible by the proinflammatory stimuli in cells of various tissue origins.
7 FAT10 belongs to the ubiquitin-like protein family (Ubls), which covalently modify target substrates by binding via their C-termini containing conserved Gly-Gly motifs. 8, 9 Various other Ubls members have been identified, including NEDD8, SUMO, ISG15, ATG8, ATG12 and URM1. [10] [11] [12] Recent advances have indicated that Ubls is involved in regulating numerous processes, including cell division, DNA repair, autophagy, signal transduction and embryonic development. 10, 11, 13, 14 Thus, Ubls members have multiple essential biological effects and it is not surprising that their function (and often dysfunction) has an important role in various diseases, particularly cancer.
FAT10 has recently reported as potential regulator on cell growth and survival; deregulation of FAT10 may induce abnormal alterations in cell division, apoptosis and immune response, 15, 16 which are associated with neoplasm formation. Meanwhile, FAT10 is a downstream target of p53, and dysregulation of FAT10 expression in p53-defective cells may contribute to carcinogenesis. 17 Furthermore, FAT10 interact noncovalently with the spindle checkpoint protein MAD2 during mitosis and induce chromosomal instability, which is a hallmark of many cancers. 18, 19 Increased FAT10 expression has been reported in several types of cancers, including colorectal tumors, gastric tumors and gynecological tumors. 20, 21 And FAT10 overexpression is found in 90% of human HCC. 22 Studies on the liver tumorigenesis in a drug-primed mouse model have found that FAT10 is involved in the precancerous lesion formation and neoplasia formation. 23, 24 In addition, a recent study has reported that the overexpression of FAT10 in HCC is a consequence of a proinflammatory immune response. 25 These findings raised the question of whether FAT10 has a role in HBVrelated hepatic oncogenesis, resulting in the development and progression of HBV-related HCC. However, there has been little research into the influence of FAT10 on the progression and prognosis of HBV-related HCC. Also, the precise role of FAT10 in pathogenesis and the molecular mechanism involved is unclear.
Herein, we first report that FAT10 expression is correlated with recurrence and poor prognosis in HBV-related HCC. We also report that ectopic expression of FAT10 promotes the proliferation, invasion and EMT of HCC cells via activation of the Akt/GSK3b pathway. These findings may have implications for the role of FAT10 in the progression of HBV-related HCC.
RESULTS
FAT10 expression is correlated with the progression and outcome of HBV-related HCC To investigate the oncogenic role of FAT10 in HBV-related HCC progression, we first examined the expression of FAT10 by realtime RT-PCR and western blotting. FAT10 expression was higher in HCC tissues compared with the matched adjacent non-tumorous liver tissues (Figures 1a-c) . These findings were further confirmed by detecting FAT10 expression by immunohistochemical analysis in paraffin-embedded, archived tissues including 260 HBV-related HCC tissues and 80 non-tumorous liver tissues. We found that 169 (65.0%) out of 260 HCC specimens showed high FAT10 expression, whereas only 4 (13.3%) out of 30 normal liver tissue specimens and 11 (22%) out of 50 cirrhosis specimens showed high FAT10 expression ( Figure 1d ). These findings strongly indicated that FAT10 is overexpressed in HBV-related HCC.
Next, we analyzed the association between FAT10 expression and clinicopathological parameters in 260 HCC patients (Table 1  and Supplementary Table S1 ). Statistical analyses revealed that FAT10 expression strongly correlated with the distant metastasis (P ¼ 0.011) and tumor recurrence (P ¼ 0.016), indicating that FAT10 overexpression is associated with the clinical progression of human HBV-related HCC.
Furthermore, we found that patients whose tumors showed high FAT10 expression had significantly shorter survival time than those whose tumors showed low FAT10 expression (Figure 2a , n ¼ 260, P ¼ 0.001) by Kaplan-Meier analysis and the log-rank test.
Notably, FAT10 expression also correlated significantly with overall survival in the subgroups of patients with tumor recurrence or tumor recurrence plus high alpha-fetoprotein (AFP) level ( Figures  2b and d) , whereas, there was no correlation in the subgroups of tumor recurrence-free or tumor recurrence-free plus low AFP level (Figures 2c and e) . In addition, univariate and multivariate analysis showed that (BCLC) stage, tumor recurrence and FAT10 expression were each recognized as independent prognostic factors in HBV-related HCC ( Table 2 ), suggesting that FAT10 has potential clinical value as a predictive biomarker for disease outcome in HBV-related HCC.
FAT10 promotes tumor cell growth, inhibits cell apoptosis and induces cell cycle progression To further investigate the biological role of FAT10 in HCC, we developed stable clones with FAT10 overexpression from HepG2 and SMMC-7721 cells, which exhibit relatively low expression of FAT10 among HCC cell lines (Figures 3a and b) . We found that FAT10-overexpressing cells showed a significantly higher in vitro proliferation rate than control or vector-transfected cells (Po0.001) (Figure 3c ). FAT10-overexpressing cells (HepG2-LV-FAT10) also generated larger xenografts in nude mice than the control, indicating that FAT10 stimulated in vivo tumor growth (Figures 3d and e) . To verify the specificity of this tumor-promoting effect, we knocked down FAT10 by small interfering RNA (siRNA) in Huh7 cells, which normally show relatively high FAT10 expression (Figures 3a and b) . We found that downregulation of FAT10 strongly inhibited tumor growth (Po0.05) (Figure 3c ). Collectively, these results suggested that FAT10 could promote HCC cell proliferation in vitro and in vivo.
To understand the mechanism by which FAT10 contributes to tumor cell proliferation, we analyzed changes of the cell cycle in FAT10-overexpressing or -knockdown cells. FAT10 overexpression was associated with an increase of cells entering S phase and a (Figure 4b ). After knockdown of FAT10 by specific siRNA, both FACS analysis and the BrdU incorporation assay showed a significant decrease of cells in S phase (Figures 4a and b) , further suggesting that FAT10 has a role in regulating cell proliferation and the cell cycle. This conclusion was further confirmed by examining proliferation-and cell cyclerelated proteins. Expression of cyclin D1, c-myc, CDK4 and CDK6 was significantly upregulated in FAT10-overexpressing cells, whereas expression of these proteins was downregulated in FAT10-knockdown cells (Figure 4c ). Moreover, FAT10-overexpressed xenograft in nude mice showed strong staining for PCNA, c-myc and cyclin D1 (Figure 4d ). These results suggested that FAT10 promotes cell proliferation by facilitating cell cycle progression. We further examined the effect of FAT10 on cell apoptosis. After silencing FAT10 expression in HCCLM3 or FAT10-overexpressing cells (HepG2-LV-FAT10), both annexin-V/propidium iodide staining (Figures 5a and b) and TUNEL assay (Figure 5c ) showed an increased apoptosis rate. Moreover, when treated with 5-fluorouracil (100 mM for 36 h) in these indicated cells, there displayed an even more significant increase of apoptosis rate. Consistent with these observation, the apoptosis indicator, cleaved poly (ADP-ribose) polymerase and cleaved caspase-3 were evidently detected by western blot analysis after FAT10 knockdown, and their expression was even increased after 5-fluorouracil treatment (Figures 5d and e) , suggesting that silencing of FAT10 induce HCC cell apoptosis via caspase-3 and poly (ADP-ribose) polymerase activation and may, to some extent, influence HCC cell chemosensitivity to 5-fluorouracil.
FAT10 induces the EMT and enhances tumor cell invasion
Our clinical analysis found that FAT10 overexpression was significantly correlated with HCC tumor recurrence. We next asked if FAT10 would affect HCC cell invasion. As expected, by the cell invasion assay, FAT10-overexpressing cells exhibited a significant increase of invasiveness, whereas FAT10 knockdown showed significantly decrease invasiveness (Po0.005; Figure 6a ). EMT was a key initial step during tumor invasion. Interestingly, we found that FAT10 itself was sufficient to induce the EMT process in HCC cells. After we developed stable clones overexpressing FAT10 from HepG2 and SMMC-7721 cells, we found a dramatic morphological change of these FAT10-overexpressing cells, with the polygonal cells seen under normal culture conditions becoming spindle-like fibroblastic cells (Figure 6b ), which is one of the main characteristics of the EMT. At the molecular level, there was a corresponding decrease in expression of the epithelial marker E-cadherin and an increase in expression of the mesenchymal marker N-cadherin and vimentin ( Figure 6c ). After silencing of FAT10 expression in Huh7, HCCLM3 and Hep3B cells, their morphology also changed from mesenchymal phenotype to epithelial phenotype, accompanied with E-cadherin expression increased and N-cadherin and vimentin expression decreased (Figures 6b and c) . Furthermore, we also found that snail, an E-cadherin transcriptional suppressor, was elevated in FAT10-overexpressing cells and was significantly reduced in FAT10-knockdown cells (Figure 6c ). Overall, these findings demonstrate that FAT10 could regulate the phenotypic shift of EMT/MET and inducing cell invasion.
It has been reported that b-catenin is overexpressed in HCC and its accumulation in tumor cells might contribute to a decrease of E-cadherin expression and induction of the EMT. 26 Immunofluorescence staining demonstrated that b-catenin mainly accumulated in the nuclei of FAT10-overexpressing cells, whereas it mainly displayed a cytoplasmic distribution in FAT10-knockdown cells (Figure 6d ), indicating that changes of FAT10 expression led to subcellular redistribution of b-catenin.
Similarly, we found lower expression of E-cadherin and higher expression of N-cadherin, vimentin and snail being observed in FAT10-overexpressing tumors in xenografts (Figure 6e ), suggesting that FAT10 enhances the EMT in vivo.
Akt/GSK3b acts as the downstream component of FAT10 and contributes to the effects of FAT10 in HCC cells To investigate the molecular basis of FAT10-mediated promotion of tumor cell proliferation, apoptosis, invasion and the EMT, we first assessed the activation of several signaling pathways. It has been reported that FAT10 induces the activation of NF-kB, 27 but we did not find FAT10 could activate this pathway (data not shown). Among the pathways we screened, Akt was found to be 28, 29 We found that phosphorylated Akt was significantly elevated in FAT10-overexpressing cells, whereas it was reduced in FAT10-knockdown cells (Figure 7a ). Activated Akt could regulate many downstream targets, such as GSK3b, MDM2, FKHR, BAD and mammalian target of rapamycin, and eventually influence cell proliferation, differentiation and apoptosis. 30 We found that the upregulation or downregulation of FAT10 could influence serine/ threonine protein kinase GSK3b inactivated by phosphorylation at serine 9, whereas FAT10 has no effect on other AKT downstream molecular (Figure 7a ). The expression of Akt and GSK3b varied with FAT10 expression (Supplementary Figure 1) . Meanwhile, the effect of FAT10 on regulation of GSK3b could be partly abolished by the phosphoinositide-3-kinase inhibitor LY294002, Akt inhibitor Triciribine or Akt specific siRNA (Figures 7b-d) . Furthermore, the enhanced proliferative and invasion capacity in HCC cells caused by overexpressing FAT10 was significantly suppressed by LY294002 (Figures 7e and f) , demonstrating that this signaling is crucial for FAT10-mediated function. These data indicated that upregulation of FAT10 activates the Akt/GSK3b pathway in HCC cells.
DISCUSSION
The present study demonstrated that FAT10 was overexpressed in HBV-related HCC specimens. Similar results have been obtained by two other investigations, although the number of tumors analyzed was considerably smaller and the etiopathogenesis was different. 22 The values had statistically significant differences.
FAT10 promotes HCC progression via Akt/GSK3b pathway L Liu et al expression was an independent prognostic indicator for HBV-related HCC survival. The overall 5-year survival rate of HCC patients following surgical intervention remains poor, which is largely attributable to the high rates of tumor recurrence. 31, 32 Meanwhile, it is difficult to devise the optimum follow-up protocol and interval for reviewing patients after surgery to detect recurrence. Hence, it is important to identify factors leading to the recurrence of HCC. Previous studies found that FAT10 has a close relationship with liver oncogenesis. 33 The present study demonstrated that FAT10 overexpressed in recurred tumors and was a poor prognostic indicator, strongly suggesting that HCC patients with high FAT10 expression should undergo follow-up at shorter intervals and be kept under close surveillance.
It is well known that high-proliferative activity and resistance to death of tumor cells are related to an elevated risk of recurrence. 34, 35 In this study, we found that FAT10 promotes HCC cell proliferation by inducing cell cycle progression and regulating cell cycle-related proteins (including cyclin D1, PCNA, CDK4 and CDK6). Previous studies have shown that high FAT10 expression increases chromosomal instability by reducing kinetochore localization of MAD2 during the prometaphase of the cell cycle and that FAT10 expression is cell cycle-regulated. 19, 20 In the present study, a possible explanation for the proliferative and cell cycle-regulating effects of FAT10 is may be its influence on the Akt/GSK3b pathway. Stimulation of this pathway by FAT10 leads to activation of Akt and inhibition of GSK3b, and also increases cyclin D1 and c-myc protein levels. Furthermore, the inhibition of this pathway by using specific Akt siRNA or Akt inhibitor reduced the proliferative activity of FAT10-overexpressing cells.
There is accumulating evidence that the EMT confers invasive capacity and multidrug resistance on tumor cells. 36 Thus, the EMT may have a critical role in tumor progression. 37, 38 In the present study, we showed that FAT10 facilitated HCC cell invasion and induced the EMT by reducing expression of the epithelial marker E-cadherin and increasing expression of the mesenchymal marker N-cadherin and vimentin. Our findings also indicated that ectopic expression of FAT10 induced translocation of b-catenin from the cytoplasm to the nucleus, where it would be involved in transcription of EMT-related genes. Furthermore, the EMT-related transcription factors snail1 showed changes related to the EMT program. Therefore, this study has provided the first evidence that FAT10 is itself sufficient to induce the EMT program.
Moreover, we demonstrated that Akt was highly activated in HCC cells and had an indispensable role in mediating the functions of FAT10. Akt signaling has been well known to be involved in cell proliferation, survival and apoptosis that affect the and c-myc, and downregulation of E-cadherin. Aberrant expression of FAT10 occurs in many other solid tumors, but its effects in these cancers are currently unknown. Whether FAT10 has an important role in other malignancies through the Akt/ GSK3b pathway is worth exploring, and the results would help us to better understand the influence of FAT10 in cancer. In summary, we demonstrated that FAT10 is overexpressed in HBV-related HCC and its expression is correlated with the clinical outcome. In addition, we identified FAT10 as a key regulator of HCC cell proliferation, apoptosis, invasion and the EMT via activation of the Akt/GSK3b pathway. Our data strongly suggested that FAT10 can be used as a prognostic marker for HBV-related HCC and that it is a potential therapeutic target. Further delineation of the mechanism of FAT10 overexpression in HCC is needed, particularly the molecule(s) to which it binds when modulating tumor cell behavior.
MATERIALS AND METHODS

Patients' characteristics and tissue samples
For the use of these clinical materials for research purposes, prior patient consent and approval from the Institute Research Ethics Committee were obtained. A total of 260 patients who had undergone surgery at the Nanfang Hospital affiliated to the Southern Medical University (Guangzhou, China) from January 2004 to July 2008 were enrolled in this study. The HCC samples were collected from patients who were histologically and clinically diagnosed at the Nanfang Hospital. All the patients were not pretreated with radiotherapy or chemotherapy before surgery. All patients were followed up for 5 years. Clinical information about the patients is described in detail in Supplementary Table S1 IHC and evaluation of staining IHC staining was performed using a Dako Envision System (Dako, Carpinteria, CA, USA) following the manufacturer's recommended protocol. Primary antibodies were listed in the Supplementary Table S2 .
The IHC-stained tissue sections were scored separately by two pathologists blinded to the clinical parameters. For FAT10 assessment, the entire tissue section was scanned to assign the scores. The staining intensity was scored as 0 (negative), 1 (weak), 2 (medium) and 3 (strong). The extent of staining was scored as 0 (0%), 1 (1-25%), 2 (26-50%), 3 (51-75%) and 4 (76-100%), according to the percentages of the positive staining areas in relation to the entire carcinoma-involved area or the entire section for the normal samples. The sum of the intensity and extent scores was used as the final staining score (0-7) for FAT10. This relatively simple, reproducible scoring method gives highly concordant results between independent evaluators and has been used in previous studies. 41, 42 For the purpose of statistical evaluation, the cutoff for the definition of subgroups was determined after measuring P-values by a logrank test between two groups from all possible combinations based on the FAT10 expression, 43 and we defined a final staining score of X3 as the high-expression group (positive group).
Cell transfection and clone selection
We constructed lentiviral vectors encoding the human FAT10 gene in pENTR221 vector (GeneCopoeia, Rockville, MD, USA) and designated them as LV-FAT10. LV-FAT10 or empty vector was transfected into the HCC cells with a multiplicity of infection 20 in the presence of polybrene (6 mg/ml) for 4 h. After 24 h, the original medium was replaced with fresh medium. For the generation of stable cell lines, the transfected cells were selected with 5 mg/ml puromycin, and pools of selected cells were serially diluted in a selection medium. Approximately 10 clones were isolated and analyzed by western blotting.
siRNA transfection
For siRNA-mediated FAT10 or AKT silencing, the following target siRNA sequences of FAT10 (NM_006398) were used: sense 5 0 -GAGACUAAGACGG GUAUAATT-3 0 and antisense 5 0 -UUAUACCCGUCUUAGUCUCTT-3 0 , and the siRNA sequences of AKT (NM_005163.2) were used: sense 5 0 -AGGAAGU CAUCGUGGCCAATT-3 0 and antisense 5 0 -UUGGCCACGAUGACUUCCUTT-3 0 . The RNA duplexes were synthesized by Genepharma Company (Shanghai, China). Transfection of the siRNAs in HCC cells was performed using Lipofectamine RNAiMAX Transfection Reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommended protocol. Cells were seeded onto a six-well plate 12 h before transfection. In each well, 50 pmol of siRNA or scramble sequences and 5 ml of Lipofectamine RNAiMAX were added to Opti-MEM medium, respectively. The diluted RNAi duplex and the diluted Lipofectamine RNAiMAX were mixed gently and incubated for 20 min at room temperature. The plate was incubated for 48 h until it was ready for further assays.
Real-time PCR analysis
Total RNA from different cell lines, HCC tissues and corresponding adjacent non-tumoral liver tissues were extracted with Trizol reagent (Invitrogen) and were quantified by SYBR Green assays with RT primers and SYBR Green from Takara Biotechnology (TAKARA, Dalian, China). The following primers were used for amplification of FAT10: sense primer, 5 0 -CAATGCTT CCTGCCTCTGTG-3 0 and antisense primer, 5 0 -TGCCTCTTTGCCTCATCACC-3 0 . Glyceraldehyde 3-phosphate dehydrogenase was amplified as an internal control using sense primer, 5 0 -GGGCGCCTGGTCACCAGGGCTG-3 0 and antisense primer, 5 0 -GGGGCCATCCACAGTCTTCTG-3 0 .
Western blot analysis
Cells were lysed on ice in RIPA buffer (1 Â phosphate-buffered saline, 1% NP40, 0.1% SDS, 5 mM EDTA, 0.5% sodium deoxycholate and 1 mM sodium orthovanadate) supplemented with protease inhibitor cocktail (Complete EDTA-free; Roche, Mannheim, Germany). For immunoblotting, equal amounts of cell lysates were separated on a 10-12% SDS polyacrylamide gel, electrotransferred to polyvinylidene fluoride (Immobile P; Millipore, Bedford, MA, USA) membranes and blocked in 5% skim milk. Membranes were immunoblotted with primary antibodies, listed in the Supplementary  Table S2 , overnight at 4 1C, followed by corresponding secondary antibodies conjugated to horseradish peroxidase. The signals were detected by enhanced chemiluminescence (Pierce, Rockford, IL, USA). b-actin was used as a loading control.
Immunofluorescence analysis
Cells were stained for immunofluorescence on coverslips as described previously. 44 Briefly, cells were washed with phosphate-buffered saline, fixed in 4% paraformaldehyde for 10 min and permeabilized with 0.25% Triton X-100 in phosphate-buffered saline for 5 min, followed by 1 h incubation with primary antibodies against b-catenin and then incubation with rhodamine-conjugated goat antibodies against mouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The coverslips were counterstained with 4,6-diamidino-2-phenylindole (Invitrogen) and imaged with a confocal laser-scanning microscope (Olympus FV1000, Olympus, Center Valley, PA, USA).
Flow-cytometry assay
Cells were harvested at an exponential growth phase, and single-cell suspensions containing 1 Â 10 6 cells were fixed with 70% alcohol. The cell cycle was monitored using propidium iodide staining and measured with a FACScan flow cytometer (BD Biosciences, San Jose, CA, USA), and the results were analyzed with ModFit 3.0 software (Verity Software House, Topsham, ME, USA). Apoptotic cells were evaluated by annexin-V fluorescein isothiocyanate and propidium iodide Apoptosis Detection Kit (Invitrogen) according to the manufacturer's protocol. Stained cells were then analyzed with a FACScan flow cytometer, and the data were analyzed using FlowJo software (Tree Star Inc., Ashland, OR, USA). 
Cell viability and proliferation assays
The effect of FAT10 on cell viability was examined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cell viability was expressed as a percentage of maximum absorbance of purple formazan at 560 nm from five replicates in three independent experiments. Transfected cells were also examined for cell proliferation by the BrdU assay. Cells were labeled by incubating in 10 mM BrdU (Sigma, St Louis, MO, USA) for 1 h and stained with anti-BrdU antibody (Santa Cruz). The coverslips were imaged with a confocal laser-scanning microscope (Olympus FV1000).
Transwell invasion assays
Invasion assay was performed as described before. 41, 44 Briefly, approximately 1 Â 10 5 cells were suspended in serum-free media and added to the top chambers of 24-well transwell chamber (Chemicon, Temecula, CA, USA). Normal cell culture media was added to the bottom chambers, and cells were incubated for 24 h at 37 1C. Afterwards, the membrane was fixed and stained, non-migrating cells were removed and the remaining cells were counted (10 random Â 100 fields per well). Cell counts are expressed as the mean number of cells per field of view.
Tumor xenografts in nude mice
Four-to six-week-old male nude mice were injected subcutaneously into bilateral flanks with HepG2 cells transfected with control or LV-FAT10 vector (1 Â 10 7 cells in 200 ml Dulbecco's modified Eagle's medium) to establish tumors. After 4 weeks of inoculation, all mice were killed, and tumors were harvested and weighed. The majority of samples were fixed in 4% paraformaldehyde, processed and embedded in paraffin for IHC and hematoxylin and eosin analysis. Animals were treated humanely, and all procedures were in compliance with our institutions' guidelines for the use of laboratory animals and approved by the Institutional Animal Care and Use Committee of Nanfang Hospital.
Statistical analysis
All statistical analysis was carried out using the SPSS statistical software package, version 13.0 (Abbott Laboratories, North Chicago, IL, USA). Significant differences were analyzed using Student's t-test and two-tailed distribution. Data were considered statistically significant if Po0.05. Data are expressed as mean ± s.e. between triplicate experiments performed thrice. The Mann-Whitney U-test was used to analyze the relationship between FAT10 expression and clinicopathological characteristics. Cumulative survival time was calculated by the Kaplan-Meier method and analyzed by the log-rank test. Cox proportional hazard analysis was used for univariate and multivariate analysis to determine the effect of variables on survival. For multivariate analysis, clinical variables were incorporated into the model with inclusion criteria of a P-value o0.05 in the univariate analysis.
